Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase 3 trial in depression.
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
Clinical Trials Arena on MSN
Compass stock heads north on psychedelic’s Phase III TRD success
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the ...
Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...
The company plans to meet with the FDA to discuss a rolling approval application for “COMP360,” a synthetic form of psilocybin that could become the first “classic” psychedelic cleared for the U.S.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...
Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...
Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results